Diversity In Clinical Trials
We are here to advance inclusive research and health equity.
The experience of the global patient population widely varies based on sociodemographic characteristics. To deliver effective treatments broadly and inclusively, clinical trials must reflect diverse patient representation in all phases of the drug development process.
Embedding best practices representative of an end-to-end inclusive mindset will provide better treatments for a wider patient population. This is the commitment of the Diversity in Clinical Trials Steering Committee at Medidata.
Awareness, Access, and Data Power Greater Diversity in Clinical Trials
Awareness of the State of Diversity in Clinical Trials
In a review of over 4,000 trials, Medidata found that Black participation is highly variable across disease areas and clinical trial sites. For example, although almost 15% of all enrolled US participants were Black – which is consistent with the 2020 US Census data – only 8.5% of oncology trial participants were Black. Further analysis at the site level also revealed that in certain indications, Black participation was highly concentrated to a small number of sites.
Learn more about enrollment trends across therapeutic areas, indications, and sites in our latest whitepaper.
Diverse Patient Population Access to Clinical Trials
At Medidata, we are committed to ensuring that all patients have access to treatment by breaking barriers and challenging norms in order to improve access to comprehensive, quality services. With a concentration in diversity in clinical trials, drug repurposing, and patient advocacy we are creating a better world for patients.
Data-Driven Solutions to Reduce Racial Disparities in Clinical Trials
Through the Medidata Platform, we have the industry’s largest scientific and operational dataset.
We leverage this rich and granular dataset to help reduce disparity in terms of diversity in clinical trials to innovate data-driven solutions.
- We leverage data from 30,000+ clinical trials with 9M+ patients across nearly 140 countries
- Baseline and benchmark diversity against industry
- Find key high-performing sites proven to recruit diverse patient populations
Breaking Down Barriers to Health Equity
Community
We Walk the Walk When it Comes to Diversity. Medidata continuously engages with diverse communities and government to actively drive change and improve the outreach of clinical trials awareness.
Our funding supports the production of Tu Salud, Tu Familia, a TV health program reaching 70,000 viewers every week in the D.C. Metro area. As part of our Social Innovation Lab, we created a customized Clinical Trial patient profile of the Emerson Clinic’s target demographic population and a heat map to identify high density underrepresented communities. As a result, Medidata has helped the Emerson Clinic increase access to care and patient participation in clinical trials by 30%.
Industry Thought Leaders
Our industry subject matter experts are dedicated to providing valuable data and insights to continue to improve diversity in clinical trials. Medidata recommends innovative strategies that leverage insights and technology solutions to address challenges in research, development, and commercial spaces.
Partnerships
Medidata actively reaches out to biotech, pharma, CRO, academia, other partners, institutions, organizations, and influencers to actively drive change.
In Partnership with SCRS, Medidata created a readiness assessment tool (DSAT) to help sites continually self-evaluate their capacity for recruiting and meeting the needs of diverse patient populations in clinical trials.
See more about our Partners: ACRO, SCRS, NMQF, Tigerlily, KIIH, Emerson Clinic
Useful Links
Diversity Module in Intelligent Trials
The Medidata Intelligent Trial Diversity module allows sponsors and CROs to select sites that can not only help accelerate a study, but also increase diverse representation. With this module, users can baseline and benchmark trial diversity and set informed goals based on industry performance in the same indication.
Diversity Site Assessment Tool
Medidata contributed significantly to the creation of the SCRS Diversity Site Assessment Tool (DSAT), a program to help sites consistently evaluate their practices in study enrollment and performance in order to pinpoint areas of opportunity to successfully facilitate inclusion and meet the needs of diverse patient populations in clinical trials.
Diversity in Clinical Trials Research Report
In our new research report, we set forth to assess the current state of racial diversity beyond the FDA Snapshot, using Medidata’s industry-leading clinical trial data repository.
Walking the Talk
Watch the first of a series of discussions with industry thought leaders from Medidata, AbbVie, Emerson Clinical Research and Memorial Sloan Kettering Cancer Center as they share best practices on how to transform trials design, reduce patient burden, and build sustainable community relationships.
Decentralized Clinical Trials
Decentralized clinical trials can mitigate geographical and socio economic barriers for patient recruitment. Patients can access a broader range of available studies and improve diversity in clinical trials by participating in scientific research.
The Medidata Decentralized Clinical Trials program delivers the industry’s only scalable, end-to-end offering for trial decentralization that connects trial experiences for patients, sites, and sponsors.
Patient Insights
Medidata’s Patient Insights program infuses the patient perspective into the software development life cycle to create technical solutions that improve the overall patient experience in clinical research operations.
myMedidata
myMedidata is a clinical research portal-for-life. Accessed using any web-enabled device, patients can use myMedidata to find, learn about, enroll and participate in all clinical trial activities from a single user interface.